Ofatumumab
E854986
anticancer drug
anti‑CD20 antibody
immunosuppressive agent
monoclonal antibody
multiple sclerosis drug
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Ofatumumab canonical | 1 |
| ofatumumab | 1 |
| ofatumumab (autoimmune indications) | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292248 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ofatumumab Context triple: [Genmab, product, Ofatumumab]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
E.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ofatumumab Target entity description: Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
E.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
anti‑CD20 antibody ⓘ immunosuppressive agent ⓘ monoclonal antibody ⓘ multiple sclerosis drug ⓘ |
| bindsTo | B‑lymphocyte antigen CD20 NERFINISHED ⓘ |
| blackBoxWarning |
hepatitis B virus reactivation
ⓘ
progressive multifocal leukoencephalopathy ⓘ |
| commonAdverseEffect |
headache
ⓘ
injection‑related reaction ⓘ upper respiratory tract infection ⓘ |
| currentMarketingAuthorizationHolder | Novartis NERFINISHED ⓘ |
| developer |
Genmab
NERFINISHED
ⓘ
GlaxoSmithKline NERFINISHED ⓘ |
| FDAApprovalYear | 2009 ⓘ |
| FDAMSApprovalYear | 2020 ⓘ |
| hasATCCode |
L01FA08
ⓘ
L04AA44 ⓘ |
| hasCASNumber | 679818-59-8 ⓘ |
| hasGenericName | ofatumumab NERFINISHED ⓘ |
| hasMolecularTargetClass | B‑cell surface antigen ⓘ |
| hasTradeName |
Arzerra
NERFINISHED
ⓘ
Kesimpta NERFINISHED ⓘ |
| hasUNIID | 6GBX3K8J0S ⓘ |
| indication |
B‑cell chronic lymphocytic leukemia
ⓘ
active secondary progressive multiple sclerosis ⓘ fludarabine‑ and alemtuzumab‑refractory chronic lymphocytic leukemia ⓘ primary refractory chronic lymphocytic leukemia ⓘ refractory small lymphocytic lymphoma ⓘ relapsing forms of multiple sclerosis ⓘ relapsing‑remitting multiple sclerosis ⓘ |
| isApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| isChimeric | false ⓘ |
| isFullyHuman | true ⓘ |
| isGlycoprotein | true ⓘ |
| isHumanized | false ⓘ |
| isProducedIn | mammalian cell culture ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mechanismOfAction |
induces B‑cell apoptosis
ⓘ
induces B‑cell lysis via antibody‑dependent cell‑mediated cytotoxicity ⓘ induces B‑cell lysis via complement‑dependent cytotoxicity ⓘ |
| pharmacologicalClass |
B‑cell depleting agent
ⓘ
selective immunosuppressant ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| target | CD20 NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ofatumumab Description of subject: Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
ofatumumab
this entity surface form:
ofatumumab (autoimmune indications)